NIH to Grant Exclusive License for New Anti-Progestational Agents

Summary

The National Institutes of Health is considering granting an exclusive license to Zonagen, Inc. for the use of 21 substituted progesterone derivatives as new anti-progestational agents, as described in a 1996 patent application.